arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Sana Biotechnology, Inc.

SANA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$2.27
▼ -3.4% Today
as of Oct 23, 10:36 ET
Last 30 days -28.75% Sep 14 → Oct 23
$2.19 $2.49 $2.80 $3.11 $3.41 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$2.31
High
$2.44
Low
$2.28
Volume
$2M
Avg Vol
$3M
Mkt Cap
$814M
P/E (TTM)
—
Beta
—
52w High
$5.90
52w Low
$2.22
Div Yield
—
Shares Out
$299M

Recent Press Releases & News last 60 days · 1 item

Sep 1 · 20:05 PR GlobeNewswire
Sana Biotechnology to Present at September 2026 Investor Conferences

SANA earnings at a glance

Sana Biotechnology, Inc. (SANA) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.18, compared with -$0.15 in the same quarter last year (-20%). The options market is pricing a move of about ±39.3% after the report, a range of roughly $1.38 to $3.16 from today's $2.27. Over its last 6 reports the stock rose the next day 4 times and fell 2, moving ±4.0% on average; after the most recent report on Aug 10, 2026 it moved +5.0%. That means options currently expect more movement than SANA has typically delivered. SANA beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 333%. The share price of $2.27 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.22
$5.90
1% of range
Avg surprise (last 6)
+7.1%
Avg reaction (last 6)
+0.3%
67% positive
Latest IV / EM
333%
EM ±39.3% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.59$-0.47$-0.36$-0.24$-0.13 Actual $-0.43Actual $-0.59Actual $-0.49Actual $-0.21Actual $-0.25Actual $-0.20Est $-0.22Actual $-0.16Est $-0.20Actual $-0.15Est $-0.18Actual $-0.16Est $-0.13Actual $-0.14Est $-0.15Actual $-0.13Est $-0.15 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-94M$-81M$-69M$-57M$-44M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Mon Aug 10, 2026Jun/2026 $-0.13 $-0.15 +13.3% +6.2% +5.0% earnings
Mon May 11, 2026Mar/2026 $-0.14 $-0.15 +6.7% +30.0% -8.4% earnings
Tue Mar 3, 20268K 2026-03-03 $-0.16 $-0.13 -23.1% — -2.8% earnings
Thu Nov 6, 2025Sep/2025 $-0.15 $-0.18 +16.7% — +1.0% earnings
Mon Aug 11, 2025Jun/2025 $-0.16 $-0.20 +20.0% — +6.5% earnings
Thu May 8, 2025Mar/2025 $-0.20 $-0.22 +9.1% — +0.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.25 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.21 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.49 — — — — financials
Sat Sep 30, 2023Sep 2023 — — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.59 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.43 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.18-$0.15 -20.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-65M$-49M—$-44M$-95M$-51M—$-62M
Net income$-64M$-47M—$-42M$-94M$-49M—$-60M
EPS (diluted)$-0.22$-0.17—$-0.16$-0.39$-0.21—$-0.25

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$57M$84M$72M$103M$71M$96M$128M$127M
Inventory————————
Total current assets$171M$112M$149M$162M$83M$113M$161M$210M
Total assets$432M$374M$417M$435M$362M$445M$501M$559M
Long-term debt————————
Total liabilities$277M$254M$256M$240M$239M$236M$251M$267M
Total equity$155M$119M$161M$195M$123M$209M$251M$292M

Implied volatility — last 90 days

101%469%838%1206%1575% Jun 08 — IV 212% · EM ±28.0%Jun 09 — IV 241% · EM ±30.1%Jun 10 — IV 165% · EM ±19.5%Jun 11 — IV 291% · EM ±32.1%Jun 12 — IV 310% · EM ±31.7%Jun 15 — IV 243% · EM ±17.5%Jun 17 — IV 1264% · EM ±52.8%Jun 19 — IV 136% · EM ±30.2%Jun 22 — IV 139% · EM ±29.0%Jun 23 — IV 212% · EM ±43.3%Jun 24 — IV 245% · EM ±49.1%Jun 25 — IV 236% · EM ±46.2%Jun 26 — IV 298% · EM ±57.0%Jun 29 — IV 270% · EM ±47.8%Jun 30 — IV 292% · EM ±50.4%Jul 01 — IV 311% · EM ±52.0%Jul 02 — IV 338% · EM ±54.7%Jul 03 — IV 351% · EM ±54.9%Jul 06 — IV 177% · EM ±24.6%Jul 07 — IV 198% · EM ±26.2%Jul 08 — IV 260% · EM ±32.6%Jul 09 — IV 452% · EM ±53.4%Jul 10 — IV 594% · EM ±65.7%Jul 13 — IV 756% · EM ±63.2%Jul 14 — IV 852% · EM ±61.6%Jul 15 — IV 978% · EM ±57.7%Jul 16 — IV 906% · EM ±37.9%Jul 20 — IV 101% · EM ±23.9%Jul 21 — IV 140% · EM ±32.4%Jul 22 — IV 135% · EM ±31.0%Jul 23 — IV 222% · EM ±49.8%Jul 24 — IV 228% · EM ±50.3%Jul 27 — IV 248% · EM ±51.8%Jul 28 — IV 282% · EM ±57.8%Jul 29 — IV 247% · EM ±49.4%Jul 30 — IV 236% · EM ±46.2%Jul 31 — IV 284% · EM ±54.3%Aug 03 — IV 248% · EM ±44.0%Aug 04 — IV 305% · EM ±52.5%Aug 05 — IV 358% · EM ±59.8%Aug 06 — IV 363% · EM ±58.7%Aug 07 — IV 364% · EM ±56.8%Aug 10 — IV 440% · EM ±60.9%Aug 11 — IV 498% · EM ±65.8%Aug 12 — IV 521% · EM ±65.3%Aug 13 — IV 554% · EM ±65.4%Aug 14 — IV 510% · EM ±56.3%Aug 17 — IV 610% · EM ±50.9%Aug 18 — IV 724% · EM ±52.3%Aug 19 — IV 1032% · EM ±60.9%Aug 20 — IV 1575% · EM ±65.8%Aug 24 — IV 190% · EM ±39.7%Aug 25 — IV 151% · EM ±30.8%Aug 26 — IV 143% · EM ±28.6%Aug 27 — IV 153% · EM ±29.9%Aug 28 — IV 158% · EM ±30.3%Aug 31 — IV 197% · EM ±34.9%Sep 01 — IV 224% · EM ±38.5%Sep 02 — IV 189% · EM ±31.5%Sep 03 — IV 201% · EM ±32.5%Sep 04 — IV 229% · EM ±35.7%Sep 07 — IV 258% · EM ±35.7%Sep 08 — IV 479% · EM ±63.2%Sep 09 — IV 475% · EM ±59.6%Sep 10 — IV 384% · EM ±45.3%Sep 11 — IV 333% · EM ±36.7%Sep 14 — IV 482% · EM ±40.2%Sep 15 — IV 656% · EM ±47.5%Sep 16 — IV 374% · EM ±22.1%Sep 17 — IV 888% · EM ±37.1%Sep 21 — IV 209% · EM ±43.5%Sep 22 — IV 251% · EM ±51.4%Sep 23 — IV 203% · EM ±40.6%Sep 24 — IV 190% · EM ±37.2%Sep 25 — IV 105% · EM ±20.0%Sep 28 — IV 201% · EM ±35.6%Sep 29 — IV 198% · EM ±34.1%Sep 30 — IV 113% · EM ±18.9%Oct 01 — IV 223% · EM ±36.1%Oct 02 — IV 199% · EM ±31.1%Oct 05 — IV 222% · EM ±30.7%Oct 06 — IV 179% · EM ±23.6%Oct 08 — IV 333% · EM ±39.3%

Sector peers

CADL
Candel Therapeutics, Inc.
$777M $8.04-3.9%
FDMT
4D Molecular Therapeutics, Inc.
$765M $11.09-12.1%
GLUE
Monte Rosa Therapeutics, Inc.
$868M $10.65-5.1%
DNA
Ginkgo Bioworks Holdings, Inc.
$738M $9.70-3.1%
SLDB
Solid Biosciences Inc.
$734M $5.81-9.4%
PRME
Prime Medicine, Inc.
$707M $3.41-10.6%

SANA earnings FAQ

When is SANA's next earnings date?

Sana Biotechnology, Inc. is expected to report on November 5, 2026.

What is SANA's expected move for earnings?

Options currently price a move of about ±39.3%, or $0.89 per share either way from $2.27.

How does SANA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±4.0%, up 4 times and down 2 times.

What EPS are analysts expecting from Sana Biotechnology, Inc.?

The consensus estimate is -$0.18 per share, versus -$0.15 a year ago.

What is SANA's implied volatility?

SANA's at-the-money implied volatility is about 333% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in